Table 1.
Demographic and Treatment Characteristics for Unmatched Cohorts
| Characteristic | NM (n=318) | ES-M (n=258) | LS-M (n=190) | ML (n=1478) |
|---|---|---|---|---|
| Age at Date of Tissue Acquisition for IMPACT Sequencing, median (IQR), years | 67.7 (62.7–73.5) | 68.0 (60.1–74.2) | 65.2 (58.0–71.1) | 66.5 (58.8–73.6) |
| Sex | ||||
| Female | 233 (73.3) | 159 (61.6) | 123 (64.7) | 898 (60.8) |
| Male | 85 (26.7) | 99 (38.4) | 67 (35.3) | 580 (39.2) |
| Race | ||||
| Asian | 28 (8.8) | 28 (10.9) | 35 (18.4) | 170 (11.5) |
| Black | 10 (3.1) | 9 (3.5) | 14 (7.4) | 83 (5.6) |
| Other | 14 (4.4) | 15 (5.8) | 12 (6.3) | 80 (5.4) |
| White | 266 (83.6) | 206 (79.8) | 129 (67.9) | 1145 (77.5) |
| Smoking History | ||||
| Ever | 240 (75.5) | 188 (72.9) | 122 (64.2) | - |
| Never | 78 (24.5) | 70 (27.1) | 68 (35.8) | |
| Clinical Stage | ||||
| I | 266 (83.6) | 137 (53.1) | 14 (7.4) | |
| II | 34 (10.7) | 57 (22.1) | 5 (2.6) | |
| III | 17 (5.3) | 58 (22.5) | 2 (1.1) | - |
| IV | 0 (0) | 0 (0) | 169 (88.9) | |
| Unknown | 1 (0.3) | 6 (2.3) | 0 (0) | |
| Pathologic Stage | ||||
| I | 249 (78.3) | 99 (38.4) | 0 (0) | |
| II | 46 (14.5) | 58 (22.5) | 0 (0) | - |
| III | 23 (7.2) | 101 (39.1) | 0 (0) | |
| IV | 0 (0) | 0 (0) | 190 (100) | |
| Surgery | ||||
| Yes | 100 (0) | 241 (93.4) | 32 (16.8) | - |
| No | 0 (0) | 17 (6.6) | 158 (83.2) | |
| Treatment Prior to IMPACT Sequencing | ||||
| Yes | 16 (5.0) | 41 (15.9) | 2 (1.1) | 1116 (75.5) |
| No | 302 (95.0) | 217 (84.1) | 188 (98.9) | 362 (24.5) |
| Type of Treatment Prior to IMPACT Sequencing | ||||
| Chemotherapy | 14 (4.4) | 35 (13.6) | 0 (0) | 513 (34.7) |
| Immunotherapy | 2 (0.6) | 2 (0.8) | 0 (0) | 216 (14.6) |
| Targeted Therapy | 1 (0.3) | 5 (1.9) | 2 (1.1) | 346 (23.4) |
| Radiation | 2 (0.6) | 5 (1.9) | 0 (0) | 845 (57.2) |
| Neoadjuvant Therapy | ||||
| Yes | 16 (5.0) | 40 (15.5) | 0 (0) | - |
| No | 302 (95.0) | 201 (77.9) | 32 (16.8) | |
| NA | 0 (0) | 17 (6.6) | 158 (83.2) | |
| Type of Neoadjuvant Therapy | ||||
| Chemotherapy | 14 (4.4) | 35 (13.6) | ||
| Immunotherapy | 2 (0.6) | 2 (0.8) | - | - |
| Targeted Therapy | 1 (0.3) | 3 (1.2) | ||
| Radiation | 2 (0.6) | 5 (1.9) | ||
| Adjuvant Therapy | ||||
| Yes | 51 (16.0) | 100 (38.8) | 8 (4.2) | |
| No | 267 (84.0) | 126 (48.8) | 14 (7.4) | - |
| NA | 0 (0) | 32 (12.4) | 168 (88.4) | |
| Type of Adjuvant Therapy | ||||
| Chemotherapy | 48 (15.1) | 84 (32.6) | 5 (2.6) | |
| Immunotherapy | 0 (0) | 1 (0.4) | 1 (0.5) | - |
| Targeted Therapy | 0 (0) | 2 (0.8) | 1 (0.5) | |
| Radiation | 11 (3.5) | 37 (14.3) | 1 (0.5) |
NM, nonmetastatic; ES-M, early stage metastatic; LS-M, late stage metastatic; ML, metastatic lesions; IQR, interquartile range; IMPACT, Integrated Mutation Profiling of Actionable Cancer Targets.